Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill (2022 - 2025)

Axsome Therapeutics' Goodwill history spans 4 years, with the latest figure at $12.0 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.0% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $12.0 million, changed 0.0%, while the annual FY2025 figure was $12.0 million, 0.0% changed from the prior year.
  • Goodwill for Q4 2025 was $12.0 million at Axsome Therapeutics, roughly flat from $12.0 million in the prior quarter.
  • Across five years, Goodwill topped out at $12.0 million in Q2 2023 and bottomed at $10.3 million in Q4 2022.
  • The 4-year median for Goodwill is $12.0 million (2023), against an average of $11.8 million.
  • The largest annual shift saw Goodwill rose 16.8% in 2023 before it dropped 0.35% in 2024.
  • A 4-year view of Goodwill shows it stood at $10.3 million in 2022, then grew by 16.8% to $12.0 million in 2023, then changed by 0.0% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Goodwill are $12.0 million (Q4 2025), $12.0 million (Q3 2025), and $12.0 million (Q2 2025).